Care Journal

Use case · Mature

Keep proving the value, year after year.

New entrants, biosimilars and guidelines that moved. Show the value is still there, with data from this year.

See what’s in the data →

Why it changes

You launched. Now the questions get bigger.

A competitor entered the class. A biosimilar moved what your payer will pay. The guideline changed. Every one of those is answerable with the patients you have now.

What you get

Four things that grow your position.

  1. Prove the value is still there

    Outcomes and resource use from the patients you have now. That’s what a renewal conversation actually turns on.

  2. Benchmark against what entered the class

    Quantify how you perform against new entrants, biosimilars and generics in the same patients, side by side.

  3. Catch care variation early

    Spot where practice is drifting and where outcomes are slipping, while it is still a regional pattern.

  4. Find the label expansion

    The off-label use that’s already happening, with the outcomes attached. That’s where the next indication argument starts.

Where teams use it

Seven jobs this does after year three.

  • Contract renewal evidence

    Medical Affairs · PV

  • Competitive and biosimilar benchmarking

    HEOR

  • Payer-stratified performance

    Market Access

  • Safety signal monitoring

    Medical Affairs

  • Refreshed value narrative

    Commercial Strategy

  • Guideline adherence education

    Market Access

  • Label expansion opportunities

    R&D · Medical Affairs

Renewal coming up? Send us the question they will ask. We’ll show you what we can put in front of them.

Bring us the renewal date.

We’ll show you exactly what the data supports by then, so you can plan the conversation around it.